Siamab Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Siamab Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10557
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Siamab Therapeutics Inc (Siamab Therapeutics), formerly Sialix Inc, is a biopharmaceutical company that focuses on the development of novel medicines targeting cancer-specific carbohydrate antigens. Its ST1 program targets a tumor associated carbohydrate antigen present in solid tumors. Siamab Therapeutics developed a technology platform that enables the discovery of large numbers of highly specific anti-TACA (tumor associated carbohydrate antigens) antibodies to kill cancer cells and also re-engage the immune system and overcome chemo-resistance.The company develops therapies in the areas of abnormal carbohydrates, glycans, ovarian, pancreatic, prostate, colon, breast and other solid tumors. Siamab Therapeutics is headquartered in Newton, Massachusetts, the US.

Siamab Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11
Siamab Therapeutics Raises USD2 Million in Venture Financing 12
Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13
Sialix Raises US$2.5 Million In Venture Financing 14
Sialix Raises US$4 Million In Series B Financing 15
Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16
Partnerships 17
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17
Licensing Agreements 18
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Siamab Therapeutics Inc – Key Competitors 19
Siamab Therapeutics Inc – Key Employees 20
Siamab Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Product News 22
04/04/2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018 22
Clinical Trials 23
May 01, 2018: Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget 23
Jan 03, 2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase 2018 24
Oct 30, 2017: Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 25
Oct 03, 2017: Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models 26
Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017 27
Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data On ST-1 at the AACR Annual Meeting 2017 28
Mar 21, 2017: Siamab Therapeutics to Present New Preclinical Data for Its Novel Antibodies and Antibody Drug Candidates at the American Association for Cancer Research Annual Meeting 2017 29
Mar 08, 2017: Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11
Siamab Therapeutics Raises USD2 Million in Venture Financing 12
Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13
Sialix Raises US$2.5 Million In Venture Financing 14
Sialix Raises US$4 Million In Series B Financing 15
Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Siamab Therapeutics Inc, Key Competitors 19
Siamab Therapeutics Inc, Key Employees 20

List of Figures
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Siamab Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pfizer Inc (PFE):企業の財務・戦略的SWOT分析
    Pfizer Inc (PFE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Maruti Suzuki India Ltd (MARUTI):企業の財務・戦略的SWOT分析
    Maruti Suzuki India Ltd (MARUTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • MedStar Health:企業の戦略的SWOT分析
    MedStar Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Public Broadcasting Service:企業の戦略・SWOT・財務分析
    Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report Summary Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Humabs BioMed SA-製薬・医療分野:企業M&A・提携分析
    Summary Humabs BioMed SA (Humabs) is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develops cellclone technologies, a proprietary …
  • Verastem Inc (VSTM):企業の財務・戦略的SWOT分析
    Summary Verastem Inc (Verastem) is a biopharmaceutical company which focus on the discovery, development and commercialization of novel small molecule drugs to treat cancer. The company’s marketed product COPIKTRA, an oral inhibitor of phosphoinositide 3-kinase (PI3K) is used to hematologic malignan …
  • Nacional Financiera S.N.C.:企業の戦略・SWOT・財務情報
    Nacional Financiera S.N.C. - Strategy, SWOT and Corporate Finance Report Summary Nacional Financiera S.N.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Dalet S.A. (DLT):企業の財務・戦略的SWOT分析
    Dalet S.A. (DLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • LGC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary LGC Ltd (LGC), formerly LGC (Teddington) Ltd is a life sciences measurement and testing company that offers reference materials, genomics solutions and analytical testing products and services. The company’s products comprise DNA extraction instrumentation, DNA extraction kits, Douglas scien …
  • Eiken Chemical Co Ltd (4549):企業の製品パイプライン分析2018
    Summary Eiken Chemical Co Ltd (Eiken Chemical), a subsidiary of Hitachi High-Technologies Corp is a medical equipment provider that offers molecular genetic products and medical devices. The company manufactures and markets clinical diagnostics and equipment, among others. It also provides fecal imm …
  • Specialty Fashion Group Ltd (SFH):企業の財務・戦略的SWOT分析
    Specialty Fashion Group Ltd (SFH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • China Overseas Land & Investment Limited:企業の戦略・SWOT・財務情報
    China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report Summary China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Cellnovo Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Cellnovo Ltd (Cellnovo), formerly Starbridge Systems Ltd is a provider of conventional diabetes care technology solutions. The company offers mobile diabetes management systems such as insulin patch pump, cellular-enabled wireless touchscreen handset with integrated blood glucose meter, acti …
  • Continental Resources, Inc.:企業の戦略・SWOT・財務分析
    Continental Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Continental Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bank Of The Philippine Islands
    Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report Summary Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • AdvanDx Inc-医療機器分野:企業M&A・提携分析
    Summary AdvanDx Inc (AdvanDx), a subsidiary of OpGen Inc is a healthcare solution provider that offers rapid and accurate molecular diagnostic tests for identification of pathogens causing critical infections in hospitalized patients. The company operates molecular testing of positive blood cultures …
  • Hainan Shuangcheng Pharmaceuticals Co Ltd (002693):製薬・医療:M&Aディール及び事業提携情報
    Summary Hainan Shuangcheng Pharmaceuticals Co Ltd (Shuangcheng Pharma) is a pharmaceutical company that develops, manufactures and markets generic peptide drugs, finished dosages and active pharmaceutical ingredients. Its products include thymalfasin, thymopetin, somatostatin, levocarnitine, famotid …
  • Parker-Hannifin Corporation:企業の戦略・SWOT・財務分析
    Parker-Hannifin Corporation - Strategy, SWOT and Corporate Finance Report Summary Parker-Hannifin Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Otrum AS:企業の戦略的SWOT分析
    Otrum AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Kinder Morgan, Inc.:企業の戦略・SWOT・財務情報
    Kinder Morgan, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kinder Morgan, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆